Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases

  • Elijah Lee1
  • Wolfram Samlowski1,2
  • Brandon Reynolds3
  • Kaviyon Sadrolashrafi4
4 affiliations
  1. 1Kirk Kerkorian School of Medicine at University of Nevada (Las Vegas UNLV)
  2. 2Nevada Oncology Specialists
  3. 3Reynolds Plastic Surgery
  4. 4Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California
Read full textPDFDOICite

Abstract

Background: Cutaneous squamous cell carcinoma is a common skin malignancy in aging populations. Surgical resection and radiotherapy can result in significant morbidity, as well as functional and cosmetic impairments. PD-1 antibodies are promising treatments for locally advanced disease.

Case presentation: Two elderly men (aged 71 and 73) with locoregionally advanced head and neck tumors received neoadjuvant treatment with cemiplimab (350 mg IV every 3 weeks). Both patients presented with neurologic symptoms concerning for nerve involvement; however, perineural spread could not be identified radiographically or by limited biopsies. Both patients achieved a significant clinical response after only four doses of cemiplimab. After 4 additional doses, both patients underwent elective treatment discontinuation and surgery and radiotherapy were omitted. With over 12-month follow-up, both patients remained free of recurrence. Treatment was well-tolerated with only Grade 1 pruritus.

Conclusion: These observations are promising and suggest the feasibility of response-adapted management following cemiplimab therapy in selected patients with advanced squamous cell skin cancer with resolution of neurologic symptoms. This approach may allow for omission of surgery and radiotherapy in selected patients. Further investigation to define appropriate candidates for this approach appears warranted.

Related

  1. Transformative improvement with staggered gains in rheumatoid arthritis remission and sustained remission, but higher relapse rates: a population-based cohort study from 1990 to 2019
    Georges El Hasbani, Roslin Jose George, Sara J Achenbach +3
    RMD OpenPeer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthDOAJPMC
  2. Intracranial metastasis following intrahepatic remission in primary hepatic small cell neuroendocrine carcinoma: a case report
    Jing Cui, Yukai Gao
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Therapy-related T-lymphoblastic lymphoma following acute myeloid leukemia remission with IDH2 mutation persistence
    Jonathan J. Cho, Huan-You Wang, Grace Y. Lin +1
    Leukemia Research ReportsPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  4. Remission of myasthenia gravis following infection with SARS-CoV-2: A case report
    Che-Yu Lin, Shannon Su, Ann Yi-Chiun Chuang
    Taiwan Journal of OphthalmologyPeer-reviewedCC BY-NC-NDFull textNeurologyDOAJ
  5. In Vivo Dynamics of Immunoregulatory Lymphocyte Reconstitution: A Seven-year Longitudinal Study of Sustained Remission in Class IV Lupus Nephritis Following Rituximab Therapy
    SHAU-JIE HUNG, JENG-WEI LU, YI-JUNG HO +4
    In VivoPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{lee2026case,
  title = {{Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases}},
  author = {Elijah Lee and Wolfram Samlowski and Brandon Reynolds and Kaviyon Sadrolashrafi},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1975694},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1975694/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Case Report: Improvement in neurologic symptoms and remission following non-operative management of locally advanced cutaneous squamous cell carcinoma of the head and neck following cemiplimab therapy: two cases
AU  - Elijah Lee
AU  - Wolfram Samlowski
AU  - Brandon Reynolds
AU  - Kaviyon Sadrolashrafi
PY  - 2026
DA  - 2026/10/15
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1975694
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1975694/full
AB  - Background: Cutaneous squamous cell carcinoma is a common skin malignancy in aging populations. Surgical resection and radiotherapy can result in significant morbidity, as well as functional and cosmetic impairments. PD-1 antibodies are promising treatments for locally advanced disease.  Case presentation: Two elderly men (aged 71 and 73) with locoregionally advanced head and neck tumors received neoadjuvant treatment with cemiplimab (350 mg IV every 3 weeks). Both patients presented with neurologic symptoms concerning for nerve involvement; however, perineural spread could not be identified radiographically or by limited biopsies. Both patients achieved a significant clinical response after only four doses of cemiplimab. After 4 additional doses, both patients underwent elective treatment discontinuation and surgery and radiotherapy were omitted. With over 12-month follow-up, both patients remained free of recurrence. Treatment was well-tolerated with only Grade 1 pruritus.  Conclusion: These observations are promising and suggest the feasibility of response-adapted management following cemiplimab therapy in selected patients with advanced squamous cell skin cancer with resolution of neurologic symptoms. This approach may allow for omission of surgery and radiotherapy in selected patients. Further investigation to define appropriate candidates for this approach appears warranted.
SN  - 2234-943X
ER  -